J Cancer 2021; 12(4):1094-1104. doi:10.7150/jca.51107 This issue Cite

Review

Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields

Shiyu Liu1,2,3, Qin Zhao1,2,3, Weiyan Shi1,2,3, Zhuangzhuang Zheng1,2,3, Zijing Liu1,2,3, Lingbin Meng4, Lihua Dong1,2,3✉, Xin Jiang1,2,3✉

1. Department of Radiation Oncology, The First Hospital of Jilin University, Changchun 130021, China
2. Jilin Provincial Key Laboratory of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun 130021, China
3. NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun 130021, China
4. Department of Hematology and Medical Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA

Citation:
Liu S, Zhao Q, Shi W, Zheng Z, Liu Z, Meng L, Dong L, Jiang X. Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields. J Cancer 2021; 12(4):1094-1104. doi:10.7150/jca.51107. https://www.jcancer.org/v12p1094.htm
Other styles

File import instruction

Abstract

High-grade gliomas (HGGs) are the most common primary malignant brain tumors. They have a high degree of malignancy and show invasive growth. The personal treatment plan for HGG is based on the patient's age, performance status, and degree of tumor invasion. The basic treatment plan for HGG involves tumor resection, radiotherapy (RT) with concomitant temozolomide (TMZ), and adjuvant TMZ chemotherapy. The basic radiation technology includes conventional RT, three-dimensional conformal RT, intensity-modulated RT, and stereotactic RT. As our understanding of tumor pathogenesis has deepened, so-called comprehensive treatment schemes have attracted attention. These combine RT with chemotherapy, molecular targeted therapy, immunotherapy, or tumor-treating fields. These emerging treatments are expected to improve the prospects of patients with HGG. In the present article, we review the recent advances in RT and comprehensive treatment for patients with newly diagnosed and recurrent HGG.

Keywords: High-grade glioma, Immunotherapy, Molecular targeted drugs, Radiotherapy, Tumor-treating fields


Citation styles

APA
Liu, S., Zhao, Q., Shi, W., Zheng, Z., Liu, Z., Meng, L., Dong, L., Jiang, X. (2021). Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields. Journal of Cancer, 12(4), 1094-1104. https://doi.org/10.7150/jca.51107.

ACS
Liu, S.; Zhao, Q.; Shi, W.; Zheng, Z.; Liu, Z.; Meng, L.; Dong, L.; Jiang, X. Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields. J. Cancer 2021, 12 (4), 1094-1104. DOI: 10.7150/jca.51107.

NLM
Liu S, Zhao Q, Shi W, Zheng Z, Liu Z, Meng L, Dong L, Jiang X. Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields. J Cancer 2021; 12(4):1094-1104. doi:10.7150/jca.51107. https://www.jcancer.org/v12p1094.htm

CSE
Liu S, Zhao Q, Shi W, Zheng Z, Liu Z, Meng L, Dong L, Jiang X. 2021. Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields. J Cancer. 12(4):1094-1104.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image